Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb: Plans to take a $15 mil. pre-tax restructuring charge in the second quarter as part of its ongoing expense-reduction program, the firm announces July 2. Roughly $5.5 mil. of the charge will go toward consolidation of B&L's 14 European distribution centers for contact lenses, solutions and sunglasses into three facilities over the next 16 months beginning in July. About $1.9 mil. will go toward reorganization of Asia-Pacific operations by dividing the business segment into North and South regions, B&L says. Formation of the previously planned "global vision care business" will cost $3.6 mil. ("The Gray Sheet" June 24, In Brief) and another $4 mil. will go toward "miscellaneous actions." In addition to the restructuring charge, B&L says it "will incur one-time period costs in the range of $5 mil. during the second half of 1996." Second quarter results are expected to be released July 18...

You may also be interested in...

COVID-19: Could Lateral Flow Test Using Glycan Recognition Be A Rapid Testing Breakthrough?

UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.

Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch

As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.

PMDA Eyes More Japan-First Approvals In Access Push

Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts